CIPLA recalls 10mg solifenacin tablets due to manufacturing deviations. Affected lots from June 2021. Consumers should contact for details.
CGMP Deviations
CIPL: A recall of 10mg solifenacin tablets due to manufacturing deviations. This means the tablets may not be safe for use as intended.
CGMP deviations indicate potential quality issues in manufacturing. This could affect the safety and effectiveness of the medication. However, the exact risk is not specified in the recall.
Prescription users of solifenacin tablets in the US. Those who have the specific lot number GG90819 from June 2021 are most at risk.
Check for the lot number GG90819 on the bottle. The product was manufactured for Cipla USA, Inc. in Sunrise, Florida, and expires June 2021.
Look for the lot number GG90819 on the bottle label.
CIPLA recalls 10mg solifenacin tablets due to manufacturing deviations.
Check for the lot number GG90819 on the bottle label. The product was manufactured for Cipla USA, Inc. in Sunrise, Florida, and expires June 2021.
The recall does not specify a remedy, so contact CIPLA for further instructions.
We’ve drafted a message you can send CIPLA to request your refund or repair — edit it as you like.
Subject: Recall D-0660-2021 — CIPLA CIPLA Hello, I own a CIPLA that is covered by recall D-0660-2021 from CIPLA. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
